This HTML5 document contains 89 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n10http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/bindingdb/
n26http://linked.opendata.cz/resource/AHFS/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/pubchem-compound/
foafhttp://xmlns.com/foaf/0.1/
n6http://linked.opendata.cz/resource/drugbank/company/
n17http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/iuphar/
n4http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/guide-to-pharmacology/
n29http://www.drugs.com/cons/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/patent/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/medicinal-product/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/chemspider/
n5http://linked.opendata.cz/ontology/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n23http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/wikipedia/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00692/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/atc/
n24http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00692
rdf:type
n5:Drug
n5:description
A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of raynaud disease and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease. [PubChem]
n5:dosage
n17:271B4673-363D-11E5-9242-09173F13E4C5 n17:271B4674-363D-11E5-9242-09173F13E4C5 n17:271B4675-363D-11E5-9242-09173F13E4C5 n17:271B4676-363D-11E5-9242-09173F13E4C5
n5:group
approved
n5:halfLife
19 minutes
n5:indication
Used as an aid for the diagnosis of pheochromocytoma, and may be administered immediately prior to or during pheochromocytomectomy to prevent or control paroxysmal hypertension resulting from anesthesia, stress, or operative manipulation of the tumor. Phentolamine has also been used to treat hypertensive crisis caused by sympathomimetic amines or catecholamine excess by certain foods or drugs in patients taking MAO inhibitors, or by clonidine withdrawal syndrome. Other indications include the prevention of dermal necrosis and sloughing following IV administration or extravasation of norepinephrine, decrease in impedance to left ventricular ejection and the infarct size in patients with MI associated with left ventricular failure, treatment of erectile dysfunction through self-injection of small doses combined with papaverine hydrochloride into the corpus cavernosum, and as an adjunct to the management of cocaine overdose to reverse coronary vasoconstriction following use of oxygen, benzodiazepines,and nitroglycerin.
n5:manufacturer
n6:271B466B-363D-11E5-9242-09173F13E4C5 n6:271B466C-363D-11E5-9242-09173F13E4C5 n6:271B466A-363D-11E5-9242-09173F13E4C5 n6:271B4671-363D-11E5-9242-09173F13E4C5 n6:271B466F-363D-11E5-9242-09173F13E4C5 n6:271B4670-363D-11E5-9242-09173F13E4C5 n6:271B466D-363D-11E5-9242-09173F13E4C5 n6:271B466E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n4:DB00692 n30:DB00692
dcterms:title
Phentolamine
adms:identifier
n12:502 n13:502 n14:DB00692 n15:50008789 n16:5571 n18:46506535 n20:0083-6830-02 n21:5775 n22:PA450926 n23:Phentolamine
n5:mechanismOfAction
Phentolamine produces its therapeutic actions by competitively blocking alpha-adrenergic receptors (primarily excitatory responses of smooth muscle and exocrine glands), leading to a muscle relaxation and a widening of the blood vessels. This widening of the blood vessels results in a lowering of blood pressure. The action of phentolamine on the alpha adrenergic receptors is relatively transient and the blocking effect is incomplete. The drug is more effective in antagonizing responses to circulating epinephrine and/or norepinephrine than in antagonizing responses to mediator released at the adrenergic nerve ending. Phentolamine also stimulates β-adrenergic receptors and produces a positive inotropic and chronotropic effect on the heart and increases cardiac output.
n5:packager
n6:271B4665-363D-11E5-9242-09173F13E4C5 n6:271B4666-363D-11E5-9242-09173F13E4C5 n6:271B4669-363D-11E5-9242-09173F13E4C5 n6:271B4667-363D-11E5-9242-09173F13E4C5 n6:271B4668-363D-11E5-9242-09173F13E4C5
n5:patent
n19:7575757 n19:6764678
n5:routeOfElimination
10-13% of the drug is excreted unchanged in urine, and the fate of the remainder of the drug is unknown.
n5:synonym
Phentolamin Fentolamina Vesomax Regitina Phentolamine mesylate Rogitine Phentolamine 2-(N-(m-Hydroxyphenyl)-P-toluidinomethyl)imidazoline Regitine Phentolaminum
n24:hasAHFSCode
n26:12-16-00
n5:mixture
n27:271B4664-363D-11E5-9242-09173F13E4C5 n27:271B4663-363D-11E5-9242-09173F13E4C5
n5:salt
foaf:page
n10:phentol.htm n29:phentolamine-injection.html
n5:IUPAC-Name
n7:271B467B-363D-11E5-9242-09173F13E4C5
n5:InChI
n7:271B4681-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n7:271B4680-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n7:271B467D-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n7:271B467E-363D-11E5-9242-09173F13E4C5
n5:SMILES
n7:271B467F-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n7:271B4679-363D-11E5-9242-09173F13E4C5
n5:logP
n7:271B4692-363D-11E5-9242-09173F13E4C5 n7:271B4677-363D-11E5-9242-09173F13E4C5 n7:271B467A-363D-11E5-9242-09173F13E4C5
n5:logS
n7:271B4678-363D-11E5-9242-09173F13E4C5
n24:hasATCCode
n25:C04AB01 n25:V03AB36
n5:H-Bond-Acceptor-Count
n7:271B4687-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n7:271B4688-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n7:271B4682-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n7:271B4683-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n7:271B4685-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n7:271B4684-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n7:271B4686-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
50-60-2
n5:category
n5:containedIn
n28:271B4672-363D-11E5-9242-09173F13E4C5
n5:Bioavailability
n7:271B468D-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n7:271B468F-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n7:271B4690-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n7:271B4691-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n7:271B468C-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n7:271B468B-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n7:271B468E-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n7:271B467C-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n7:271B4689-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n7:271B468A-363D-11E5-9242-09173F13E4C5